Huntington’s Disease – Epidemiology – Mature Markets
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in seven major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of the disease for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology’s HD forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HD over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following HD subpopulations:
- Diagnosed premanifest prevalence of HD.
- Diagnosed manifest prevalence of HD.
- Diagnosed manifest incident cases of HD.
- Diagnosed population at risk.
- Diagnosed manifest prevalence by disease stage.
Note: Coverage may vary by country.
Table of contents
- Huntington's Disease - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Key Updates
- Diagnosed Prevalent Cases of Manifest Huntington's Disease per 100,000 People of All Ages in 2019 and 2039
- Patient-Flow Diagram for Huntington's Disease in All Countries Under Study in 2019
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Manifest Huntington's Disease over the Next 20 Years
- Key Findings
- Epidemiology Data
- Methods
- Diagnosed Population at Risk for Huntington's Disease
- Diagnosed Incident Cases of Manifest Huntington's Disease
- Diagnosed Prevalent Cases of Huntington's Disease
- Diagnosed Prevalence of Huntington's Disease by Manifest Status
- Diagnosed Prevalent Cases of Manifest Huntington's Disease by Disease Stage
- Drug-Treated Cases of Huntington's Disease
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Huntington's Disease
- Studies Excluded from the Analysis of Huntington's Disease
- Risk/Protective Factors
- Bibliography
- Literature Review
- Introduction
Johnson Olabisi, M.B.B.S., M.Sc., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he trained as a community physician. He has also supervised and coordinated various governmental and nongovernmental public health projects. He holds a master’s degree in public health (health economics) from the London School of Hygiene and Tropical Medicine, a master’s degree in epidemiology and medical statistics, and a medical degree from the University of Ibadan in Nigeria.
Mike Hughes, M.Sc., Ph.D., is the director of the Epidemiology department at DRG, part of Clarivate. He joined DRG in 2006 and has many years’ experience in the mathematical modeling of healthcare service delivery, cardiovascular and cancer epidemiology, biostatistics, meta-analysis, and systematic reviewing. He has been principal author on many published articles in leading international journals in the areas of risk modeling in intensive care and cardiovascular medicine. He also helped develop national guidelines on behalf of NICE and the American College of Chest Physicians for the treatment of atrial fibrillation, stroke, and hypertension. He is particularly interested in modeling patient flows in cancer and methods for forecasting disease burden in noncommunicable epidemiology. Dr. Hughes received his Ph.D. in risk modeling in intensive care in 2003 from City University, London, and his Ph.D. in statistical causation and foundations of probability theory from the University of Nottingham.